Sorafenib Tosylate CAS 475207-59-1 Puritas ≥99.0% (HPLC) API Factory Quality
Commercial Supple Sorafenib Tosylate et intermedia:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolamide CAS:
4-Chloro-3-(Trifluoromethyl) phenyl Isocyanate CAS: 327-78-6
| Nomen chemicum | Sorafenib Tosylate |
| Synonyma | Nexavar;4-[4-[3-[4-Chloro-3-(Trifluoromethyl)phenyl]ureido]phenoxy]-N-Methylpicolinamide 4-Methylbenzenesulfonate;4-[4-[[4-Chloro-3-(Trifluoromethyl)phenyl]carbamamido]phenoxy]-N-Methyl-2-Pyridinecarboxamide 4-Methylbenzenesulfonate;BAV 43-9006 Tosylate |
| CAS Number | 475207-59-1 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C21H16ClF3N4O3.C7H8O3S |
| M. Pondus | 637.03 |
| Liquescens punctum | 225.0 ad 230.0℃ |
| Sensitiva | Aer Sensitivus, calor Sensitivus |
| Solubilitas | Solutum in aqua (<1 mg/ml) ad 25℃, DMSO (127 mg/ml ) ad 25℃, et Ethanol (<1 mg/ml ) ad 25℃ |
| Shipping Conditions | Refrigescant & siccum locum (2~8℃), protege a luce |
| COA & MSDS | Praesto |
| Fasciae vita | II annis, si proprie condita |
| Brand | Ruifu Chemical |
| Item | Specifications | Proventus |
| Aspectus | Lux aut Yellow aut pulveris alba | Obsequitur |
| Puritas / Analysis Methodus | ≥99.0% (HPLC) | 99.8% |
| Liquescens punctum | 225.0~230.0℃ | Obsequitur |
| Metalla gravis | ≤10ppm | <10ppm |
| Damnum in Siccatio | ≤0.50% | 0.12% |
| Residere in Ignition | ≤0.20% | 0.10% |
| Unam immunditiam | ≤0.50% | Obsequitur |
| Totalis immunditias | ≤0.50% | Obsequitur |
| NMR Imaginum | Conformat ut Structure | Obsequitur |
| Test Standard | Enterprise Standard | Obsequitur |
| Consuetudinem | Sorafenib Tosylate (CAS: 475207-59-1) in curatione RCC & HCC | |
Sarcina:Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Condite in arcte clauso vase.Condite in loco frigido, sicco (2~8℃) et cellario bene ventilato ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Periculum Codes 36/37/38 - Irritando ad oculos, systema respiratorium et cutem.
Salutis descriptio S28 - Post contactum cum cute, statim lavabit copia saponis suds.
S26 - In contactu cum oculis, statim cum aqua multa ablue et consilium medicinae quaeras.
Sorafenib Tosylate (CAS: 475207-59-1) est novum genus pharmaci antitumoris multi-scopi, a Germanico Bayer pharmaceutico enucleatum, et in experimentis animali preclinicis antitumorem expansivum ostendit.Sorafenib praesto est in tabulis CC-mg pro administratione oralis adhibenda in curatione RCC et HCC.Sorafenib Tosylate simul afficit cellas tumorem et tumorem venae sanguineae.Habet duplicem antitumorem effectum: cellam signo transductionis meatus mediante RAF/MEK/ERK obstruere potest ut directe inhibeat tumorem cellularum incrementorum, dum etiam inhibet VEGF et laminae incrementi derivatorum (PDGF) receptores ad impediendum sanguinis tumorem novum formandum. vasis fictilibus, obliquo tumore cellulae incremento inhibito.
Sorafenib Tosylate, nomen artis Nexavar, primum a Bayer Pharmaceuticis in Germania elaboratum est.Sorafenib Tosylate inhibitor multi-kinase est, qui morbos ut cancer tractare potest.Mense Decembri 2005, ab US FDA probatum est medicamentum primae lineae ad curationem cancri renalis promoventis.Mense Augusto 2009, publice in Sinis recensita est approbatione Civitatis Cibus et Administrationis medicamentis.
Sorafenib Tosylate sunt tyrosinae kinases (VEGFR et PDGFR) et RAF/MEK/ERK cascade inhibitores, simul in Raf-1, wtBRAF et V599EBRAF agentes, cum IC50 6 nM, 22 nM et 38 nM, respectively.
Sorafenib Tosylate simul inhibere potest varias kinases quae in cella et superficie cellula exsistunt, incluso RAF kinase, auctum endotheliale vascularium factoris receptoris-2 (VEGFR-2), factor incrementi endothelialis vascularis receptoris 3 (VEGFR-3), platelet ductum incrementum recepta-β (PDGFR-β), KIT et FLT-3.Videri potest quod sorafenib toluenesulfonate habet duplicem anti-tumorem effectus.Ex altera parte, protinus inhibere tumorem incrementi potest, RAF/MEK/ERK iter significans;inhibere vero potest VEGFR et PDGFR.Formationem tumoris neovascularizationis obstruunt et incrementum cellularum tumoris oblique inhibent.Sorafenib Tosylate longe efficacissimum medicamentum est ad curationem cancri iecoris progressivi per systemicam administrationem, et verisimile fiet novum pharmacum vexillum pro curatione huius morbi.
Sorafenib Tosylate semel cottidiana administratio oris humani tumoris animalis transplantationis exempla monstravit amplis activitatis anti-tumoris, inter cancrum colonicum, carcinoma non parvum, cancer pectus, melanoma, cancer pancreaticus, leukemia et cancer ovarii et mus cellula renalis carcinoma exemplar, renca exemplar.
